Rubius Therapeutics (RUBY) Raised to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Rubius Therapeutics (NASDAQ:RUBY) from a sell rating to a hold rating in a report released on Wednesday morning.

According to Zacks, “Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States. “

Other research analysts have also recently issued reports about the stock. Jefferies Financial Group started coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They issued a buy rating and a $40.00 price objective for the company. Leerink Swann started coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They issued an outperform rating for the company. Morgan Stanley started coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They issued an overweight rating and a $37.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They issued an overweight rating for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Rubius Therapeutics currently has a consensus rating of Buy and a consensus target price of $38.50.

Shares of Rubius Therapeutics stock traded down $1.14 on Wednesday, hitting $15.69. The company had a trading volume of 59,741 shares, compared to its average volume of 133,937. Rubius Therapeutics has a 52 week low of $15.06 and a 52 week high of $33.01.

Rubius Therapeutics (NASDAQ:RUBY) last posted its quarterly earnings data on Friday, August 31st. The company reported ($3.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($2.73). During the same quarter last year, the company posted ($1.25) EPS. As a group, sell-side analysts anticipate that Rubius Therapeutics will post -1.7 EPS for the current fiscal year.

Large investors have recently modified their holdings of the stock. FMR LLC bought a new stake in Rubius Therapeutics during the third quarter worth approximately $140,907,000. Artal Group S.A. bought a new stake in Rubius Therapeutics during the third quarter worth approximately $69,811,000. BlackRock Inc. bought a new stake in Rubius Therapeutics during the third quarter worth approximately $38,155,000. Alliancebernstein L.P. bought a new stake in Rubius Therapeutics during the third quarter worth approximately $39,045,000. Finally, Jennison Associates LLC bought a new stake in Rubius Therapeutics during the third quarter worth approximately $11,333,000. Hedge funds and other institutional investors own 0.01% of the company’s stock.

About Rubius Therapeutics

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.

Recommended Story: How are institutional investors different from individual investors?

Get a free copy of the Zacks research report on Rubius Therapeutics (RUBY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply